Avandia adviser amy be probed for possible conflict of interests
The US FDA is looking to investigate a member of the panel that recently recommended restrictions on rosiglitazone for conflict of interest. Dr Capuzzi was one of the panel members who voted to keep rosiglitazone on the market. However, several news organisations have reported that Dr Cauzzi has been a member of GSKs speakers’ bureau.
BMJ 2010; 241:c4083